Gyre Therapeutics, a San Diego-based biopharmaceutical company with 593 employees, focuses on developing F351 for treating NASH-associated fibrosis and has a pipeline through its indirect interest in Gyre Pharmaceuticals. The company went public on April 12, 2006, and also offers the drug ETUARY.
GYRE has been in the news recently: Alamar Biosciences will present over 30 studies on neurodegenerative disease biomarkers using its NULISA™ platform at the AAIC conference in Toronto from July 27-31, 2025. The company is also collaborating with DZNE to analyze 23,000 plasma samples with its NULISAseq™ panels to further advance biomarker discovery in aging and neurodegeneration.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
